

EXPERIENCE OF USE OF COMBINED BUDESONIDE /FORMOTEROL MEDICATION IN TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

*T. O. Pertseva, L. I. Konopkina,
O. V. Mironenko*

Summary

Combined budesonide/formoterol medication Foracort® demonstrated clinical efficacy in 35 COPD stage 3 patients, while administered for 8 weeks, influencing both bronchoconstriction and inflammation. Indirect effect of medication stimulated function of respiratory muscles and improved quality of life of the patients. In 4 weeks of therapy we noted an improvement in overall patients' condition, which lasted for 8 weeks. This is an important factor in establishing of the control over COPD. Medication was well tolerated by patients. In order to avoid side affects, such as dysphonia, it is essential to use prophylaxis procedures: spacers, mouth rinsing, etc. The medication is recommended in treatment of COPD stage 3 patients.